Patients with COPD prioritise chronic symptoms and functional impact as key outcomes in exacerbation trials
Patient priorities in COPD exacerbation trial outcomes
Introduction: Importance of patient perspectives
Introduction: Patient perspectives are essential to establish relevant outcomes in trials assessing COPD treatments.
Aim: Outcomes prioritised by patients with COPD
Aim: To assess which trial outcomes for exacerbation treatments are most important for patients with COPD.
Methods: Semi-structured interviews in COPD patients
Methods: Patients with COPD underwent semi-structured interviews where they stated what outcomes should be prioritised in clinical trials.
Comparisons were made between patients with at least one COPD hospitalisation and patients with no hospitalisations in the preceding year.
Results: Chronic symptoms and functional impact
Results: Semi-structured interviews were conducted for 70 patients in 11 countries across 4 continents (average age 66.7 years, 79.2% male).
45 patients had at least 1 admission in the previous year. 8 out of the 10 most frequently chosen outcomes focussed on chronic symptoms, such as dyspnoea (90.0%), and specific aspects affecting quality of life and function, such as reduced walking distance (70.0%) and impact on social life (57.1%).
Patients with recent hospitalisations more frequently prioritised specific components of quality of life and function. Dyspnoea was most prioritised in both groups.
Conclusions: Quality of life and function as trial outcomes
Conclusions: COPD exacerbations trials should more consistently assess the individual outcomes which contribute to overall quality of life and function, including dyspnoea.
The outcomes highlighted align with the ERS statement on a core outcome set for trials on COPD exacerbation treatments.
Authors
Sachin Ananth, Fekri Abroug, Alvar Agusti, Per Bakke, Konstantinos Bartziokas, Bianca Beghe, Andras Bikov, Thomas Bradbury, Guy Brusselle, Cordula Cadus, Courtney Coleman, Marco Contoli, Alexandru Corlateanu, Olga Corlateanu, Gerard J. Criner, Balazs Csoma, Alexander Emelyanov, Rosa Faner, Gustavo Fernandez Romero, Zeineb Hammouda, Peter Horváth, Arturo Huerta Garcia, Michael Jacobs, Christine Jenkins, Guy Joos, Olga Kharevich, Konstantinos Kostikas, Elena Lapteva, Zsofia Lazar, Joerg D. Leuppi, Carol Liddle, John Linnell, Alejandra López-Giraldo, Vanessa M. Mcdonald, Rune Nielsen, Alberto Papi, Isabel Saraiva, Galina Sergeeva, Agni Sioutkou, Pradeesh Sivapalan, Elizabeth Stovold, Hao Wang, Fuqiang Wen, Janelle Yorke, Paula R. Williamson, Jørgen Vestbo, Jens-Ulrik Jensen, Alexander G. Mathioudakis
Read more details at
Fecha de publicación
Published online 18 November 2025
Categorías asociadas al artículo
Noticias relacionadas
Addressing the Global Challenges of COPD and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)
Analysis of the global challenges of COPD and asthma and the shared vision of GOLD and GINA to improve diagnosis, access to inhaled therapies and patient outcomes worldwide.
Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD
Joint GOLD/GLI statement on spirometry to define airflow obstruction and confirm COPD diagnosis, aiming to harmonize criteria and improve global practice.
Climate change and respiratory health: implications for respiratory clinicians in primary and specialist care
Review on climate change and respiratory health, focusing on chronic respiratory diseases and implications for primary and specialist care.
cfDNA profiling in COPD
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Exploring the association between eosinophils and autoimmunity in COPD
Study exploring the association between eosinophils and circulating autoantibodies in COPD patients, considering airflow limitation and smoking status.
Lessons from the ANTES B+ study
Lessons from the ANTES B+ study highlighting challenges in COPD clinical trials, recruitment difficulties, and implications for future study design.
Imagen desarrollada ChatGPT